{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:39:23Z","timestamp":1790278763672,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00415-009-0130-0","type":"journal-article","created":{"date-parts":[[2009,4,14]],"date-time":"2009-04-14T08:17:12Z","timestamp":1239697032000},"page":"608-614","source":"Crossref","is-referenced-by-count":25,"title":["IVIg dose increase in multifocal motor neuropathy"],"prefix":"10.1007","volume":"256","author":[{"given":"Andreas","family":"Baumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Sturzenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,9]]},"reference":[{"key":"130_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"Dalakas","year":"2004","unstructured":"Dalakas MC (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102:177\u2013193","journal-title":"Pharmacol Ther"},{"key":"130_CR2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","volume":"60","author":"Dalakas","year":"2003","unstructured":"Dalakas MC, Clark WM (2003) Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 60:1736\u20131737","journal-title":"Neurology"},{"key":"130_CR3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"Federico","year":"2000","unstructured":"Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo- controlled study. Neurology 55:1256\u20131262","journal-title":"Neurology"},{"key":"130_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257\u2013259","journal-title":"Autoimmun Rev"},{"key":"130_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"Leger","year":"2001","unstructured":"Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145\u2013153","journal-title":"Brain"},{"key":"130_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mus.10317","volume":"27","author":"Olney","year":"2003","unstructured":"Olney RK, Lewis RA, Putnam TD, Campellone JV Jr (2003) Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27:117\u2013121","journal-title":"Muscle Nerve"},{"key":"130_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mus.880110203","volume":"11","author":"Parry","year":"1988","unstructured":"Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11:103\u2013107","journal-title":"Muscle Nerve"},{"key":"130_CR8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/135245859900500406","volume":"5","author":"Sharrack","year":"1999","unstructured":"Sharrack B, Hughes RA (1999) The Guy\u2019s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5:223\u2013233","journal-title":"Mult Scler"},{"key":"130_CR9","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/01.wnl.0000277697.55288.d0","volume":"69","author":"Slee","year":"2007","unstructured":"Slee M, Selvan A, Donaghy M (2007) Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 69:1680\u20131687","journal-title":"Neurology"},{"key":"130_CR10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","volume":"250","author":"Stangel","year":"2003","unstructured":"Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders \u2014 a prospective study. J Neurol 250:818\u2013821","journal-title":"J Neurol"},{"key":"130_CR11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<900::AID-MUS9>3.0.CO;2-Y","volume":"23","author":"Taylor","year":"2000","unstructured":"Taylor BV, Wright RA, Harper CM, Dyck PJ (2000) Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 23:900\u2013908","journal-title":"Muscle Nerve"},{"key":"130_CR12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/jnnp.2005.064816","volume":"77","author":"Van Asseldonk","year":"2006","unstructured":"Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, Franssen H (2006) Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 77:743\u2013747","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"130_CR13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/brain\/awg019","volume":"126","author":"Van Asseldonk","year":"2003","unstructured":"Van Asseldonk JT, Van den Berg LH, Van den Berg-Vos RM, Wieneke GH, Wokke JH, Franssen H (2003) Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 126:186\u2013198","journal-title":"Brain"},{"key":"130_CR14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/brain\/awf193","volume":"125","author":"Van den Berg-Vos","year":"2002","unstructured":"Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH (2002) Multifocal motor neuropathy: longterm clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125:1875\u20131886","journal-title":"Brain"},{"key":"130_CR15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1468-1331.2006.01466.x","volume":"13","author":"van Schaik","year":"2006","unstructured":"van Schaik IN, Bouche P, Illa I, Leger JM, Van den Bergh P, Cornblath DR, Evers EM, Hadden RD, Hughes RA, Koski CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA (2006) European Federation of Neurological Societies\/ Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 13:802\u2013808","journal-title":"Eur J Neurol"},{"key":"130_CR16","doi-asserted-by":"crossref","unstructured":"van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005) Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev:CD004429","DOI":"10.1002\/14651858.CD004429.pub2"},{"key":"130_CR17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinph.2006.09.020","volume":"118","author":"Vucic","year":"2007","unstructured":"Vucic S, Black K, Chong PS, Cros D (2007) Multifocal motor neuropathy with conduction block: Distribution of demyelination and axonal degeneration. Clin Neurophysiol 118:124\u2013130","journal-title":"Clin Neurophysiol"},{"key":"130_CR18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","volume":"63","author":"Vucic","year":"2004","unstructured":"Vucic S, Black KR, Chong PS, Cros D (2004) Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 63:1264\u20131269","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-0130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-009-0130-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-0130-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:08:21Z","timestamp":1559056101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-009-0130-0"}},"subtitle":["A prospective six month follow-up"],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["130"],"URL":"https:\/\/doi.org\/10.1007\/s00415-009-0130-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}